The Medical Advisor

Retatrutide is an investigational triple-agonist therapy that targets three metabolic hormone pathways, potentially enabling greater weight loss. In contrast, tirzepatide targets two (GLP-1 and GIP) and is FDA-approved, while semaglutide —the first of the three—targets a single pathway (GLP-1) and is also FDA-approved for weight management. The Weight Loss Revolution (2026 Update) Weight loss treatment has undergone a once-in-a-generation transformation . What started with GLP-1 drugs like semaglutide has now evolved into multi-receptor peptides capable of delivering 20–30% body weight loss—approaching bariatric surgery outcomes . ( Semaglutide vs Tirzepatide vs Retatrutide ) At the center of this revolution are three key players: Semaglutide (Ozempic, Wegovy) — first-generation GLP-1 Tirzepatide (Mounjaro, Zepbound) — dual agonist (GLP-1 + GIP) Retatrutide (next-gen) — triple agonist (GLP-1 + GIP + glucagon) The question is no longer “Do these drugs work?” It’s now: “Which one is...

Demodex mites are microscopic, eight-legged arthropods that commonly live in human hair follicles and sebaceous glands. They are often called “face mites” because they are especially associated with facial skin, eyelashes and eyebrows. The surprising part is how difficult it is to answer a seemingly simple question: How many adults actually have Demodex mites? Some studies have reported extremely high prevalence, including one molecular study in which Demodex DNA was detected in 100% of adults over 18 in a small sample . But a much larger 2025 systematic review and meta-analysis estimated a global pooled prevalence of approximately 35% across the available studies. The key lesson: “100% of adults have Demodex” is too absolute as a general population statement. The available evidence suggests that Demodex is extremely common in adults, but the measured prevalence varies dramatically according to age, population, body site and—especia...

Medically Reviewed by: Dr Frank Yap, MD | Written by: OneDayMD Editorial Team | Last Updated: September 2026 Quick Answer Cancer treatment is moving from a one-size-fits-all model toward increasingly biomarker-driven, immune-based, targeted and combination therapy .  The most consequential 2026 cancer breakthrough is daraxonrasib , an oral RAS(ON) inhibitor that nearly doubled overall survival in previously treated metastatic pancreatic cancer in the phase 3 RASolute 302 trial presented at ASCO 2026. Other major advances include the OPTIMA trial , showing many high-risk breast cancer patients can safely skip chemotherapy after genomic testing; the bispecific antibody ivonescimab , which outperformed standard immunotherapy in squamous lung cancer; continued expansion of CAR-T and cell therapies into solid tumors; and growing, evidence-tiered interest in repurposed drugs and metabolic approaches as complementary strategies. AACR 2026 and ASCO 2026 both emphasized that progress ...